Worth reading
73In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
887
¥ million (year-on-year change in revenue for FY2027)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 2026, full year8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,182 million-11.0%
Operating profit¥-549 million
Ordinary income¥-537 million
Net income¥-734 million
Selling, general and administrative expenses¥1,816 million
Results for the three months of the current quarterOperating profit for the fourth quarter of FY2026 was ¥14 million
Full-year earnings forecast
Net Sales
¥3,070 million
Operating profit
¥100 million
Ordinary income
¥110 million
Net income for the current fiscal year
¥100 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。93 Jack orders, representing 27% of the full-year forecast of 350 orders (as of 30 April 2026)
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year-on-year change in operating profit for FY2026
Decrease in eligible burn cases-54
General customer contract revenue-54
Teijin contract revenue-113
JASMINE revenue46
JACC revenue33
Nepic and Ocural revenue-19
Labsite Business revenue33
Other factors-38
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The outlook assumes and is based on a case volume in line with the previous year, cost control targeting a 10% profit margin, and increased sales and production staffing to achieve the revenue target.New initiatives
- Change the reporting segment name from "Research and Development Support Business" to "Labsite Business"
- Organizational restructuring into specialized teams for the musculoskeletal (orthopedic) and epithelial fields
- Preparation for the establishment of a German subsidiary
- Development and launch of a research-use intestinal epithelial model
- Development of new industry sectors, including medical device and materials manufacturers
- Strengthen efforts to attract technology seeds from Teijin and other companies to the Kashiwa-no-ha Regenerative Medicine Platform
Key KPIsA metric the company considers important as a management benchmark.
- Monthly Jack orders30 cases/monthYear on year against the same period last yearRecord high
- Number of facilities under contract for JACC125 Facility
- Number of facilities using Jasmine42 Facility
- Number of regular EpiSensor customers8 companies
- Jack orders93 Example
Segment results
Regenerative medicine products business
Net Sales
¥1,354 million-9.0%
Operating profit (loss)
¥78 million-64.0%
Regenerative medicine contract services business
Net Sales
¥546 million-23.0%
Operating profit (loss)
¥327 million-20.0%
Labsite business
Net Sales
¥281 million+14.0%
Operating profit (loss)
¥52 million-22.0%
Medium-term management plan targets
Target fiscal yearFY2027
Net Sales
¥5,000 million
Operating profit
¥500 million
Regenerative Medicine Products Business revenue
¥3,500 million
Regenerative Medicine Contract Business revenue
¥1,000 million
Labsite Business revenue
¥500 million
Orders received and order backlog
93 Jack orders; order backlog: Not disclosedCapital expenditures
¥77 million acquisitions of tangible and intangible fixed assets
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Net Sales | ¥2,182 million (YoY -11.0%) |
| Operating profit | ¥-549 million |
| Ordinary income | ¥-537 million |
| Net income | ¥-734 million |
| Selling, general and administrative expenses | ¥1,816 million |
| Results for the three months of the current quarter | Operating profit for the fourth quarter of FY2026 was ¥14 million |
| Full-year earnings forecast | Net Sales ¥3,070 million / Operating profit ¥100 million / Ordinary income ¥110 million / Net income for the current fiscal year ¥100 million |
| Progress against full-year forecast | 93 Jack orders, representing 27% of the full-year forecast of 350 orders (as of 30 April 2026) |
| Segment results | Regenerative medicine products business Net Sales ¥1,354 million (YoY -9.0%) / Operating profit (loss) ¥78 million (YoY -64.0%) / Regenerative medicine contract services business Net Sales ¥546 million (YoY -23.0%) / Operating profit (loss) ¥327 million (YoY -20.0%) / Labsite business Net Sales ¥281 million (YoY +14.0%) / Operating profit (loss) ¥52 million (YoY -22.0%) |
| Breakdown of Factors Affecting the Change | Year-on-year change in operating profit for FY2026 Decrease in eligible burn cases -54 / General customer contract revenue -54 / Teijin contract revenue -113 / JASMINE revenue 46 / JACC revenue 33 / Nepic and Ocural revenue -19 / Labsite Business revenue 33 / Other factors -38 |
| Key KPIs | Indicator name Monthly Jack orders / Value 30 cases/month / Year on year against the same period last year Record high, Indicator name Number of facilities under contract for JACC / Value 125 Facility / Year on year against the same period last year Not disclosed, Indicator name Number of facilities using Jasmine / Value 42 Facility / Year on year against the same period last year Not disclosed, Indicator name Number of regular EpiSensor customers / Value 8 companies / Year on year against the same period last year Not disclosed, Indicator name Jack orders / Value 93 Example / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | The outlook assumes and is based on a case volume in line with the previous year, cost control targeting a 10% profit margin, and increased sales and production staffing to achieve the revenue target. |
| Medium-term management plan targets | Target fiscal year FY2027 / Net Sales ¥5,000 million / Operating profit ¥500 million / Regenerative Medicine Products Business revenue ¥3,500 million / Regenerative Medicine Contract Business revenue ¥1,000 million / Labsite Business revenue ¥500 million |
| Capital expenditures | ¥77 million (acquisitions of tangible and intangible fixed assets) |
| Orders received and order backlog | 93 Jack orders; order backlog: Not disclosed |
| New initiatives | Change the reporting segment name from "Research and Development Support Business" to "Labsite Business", Organizational restructuring into specialized teams for the musculoskeletal (orthopedic) and epithelial fields, Preparation for the establishment of a German subsidiary, Development and launch of a research-use intestinal epithelial model, Development of new industry sectors, including medical device and materials manufacturers, Strengthen efforts to attract technology seeds from Teijin and other companies to the Kashiwa-no-ha Regenerative Medicine Platform |
Items this document does not state (13)
Gross Profit MarginOperating profit marginSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In FY2026, the decline in revenue and profit was attributable to a decrease in the number of burn cases eligible for JACE and the loss of spot income recorded in the previous year, as well as milestone income from Teijin. In FY2027, growth is expected to be driven by the expanded osteoarthritis indications for the Jack regenerative medicine product, market development for the Jasmine regenerative medicine product, progress into new phases of contract projects, and expansion into Europe and new markets for the Labsite business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.